91Ó°ÊÓ

Refer to a clinical trial named APPROVe designed to determine whether Vioxx, a medication used for \(a r\) thritis and acute pain, was effective in preventing the recurrence of colorectal polyps in patients with a history of colorectal adenomas. APPROVe was conducted between 2002 and 2003 and involved 2586 participants, all of whom had a history of colorectal adenomas. The participants were randomly divided into two groups: 1287 were given 25 milligrams of Vioxx daily for the duration of the clinical trial (originally intended to last three years), and 1299 patients were given a placebo. Neither the participants nor the doctors involved in the clinical trial knew who was in which group. During the trial, 72 of the participants had cardiovascular events (mostly heart attacks or strokes). Later it was found that 46 of these people were from the group taking the Vioxx and only 26 were from the group taking the placebo. Based on these results, the clinical trial was stopped in 2003 and Vioxx was taken off the market in 2004. Describe as specifically as you can the target population for APPROVe

Step by step solution

01

Identify Target Group

The information given in the exercise mentions that the trial was conducted on patients who had a history of colorectal adenomas. This indicates that such individuals constitute our target population.

02

Consider Other Relevant Information

The groups' division in the clinical trial is not a defining characteristic of the target population of the study. Moreover, the occurrence of heart attacks or strokes is also not indicative of the target population for the trial but rather the outcomes or results of the trial.

03

Fromulate The Answer

Based on the available information, we can conclude the target population of the APPROVe trial.

Unlock Step-by-Step Solutions & Ace Your Exams!

• Full Textbook Solutions

  Get detailed explanations and key concepts

• Unlimited Al creation

  Al flashcards, explanations, exams and more...

• Ads-free access

  To over 500 millions flashcards

• Money-back guarantee

  We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with 91Ó°ÊÓ!

Key Concepts

These are the key concepts you need to understand to accurately answer the question.

Vioxx

Vioxx was a widely used medication for arthritis and acute pain relief. Manufactured by Merck & Co., it belonged to a class of drugs known as COX-2 inhibitors. This class of drugs was designed to selectively block the COX-2 enzyme, which is responsible for pain and inflammation.
Unlike traditional nonsteroidal anti-inflammatory drugs (NSAIDs) that affect both COX-1 and COX-2 enzymes, COX-2 inhibitors like Vioxx aimed to deliver pain relief with fewer gastrointestinal side effects.
Vioxx was initially promising, providing significant relief for those with arthritis. However, during the APPROVe clinical trial, which sought to explore its efficacy in colorectal adenomas prevention, Vioxx was found to increase the risk of cardiovascular events. This led to its withdrawal from the market after the trial results were unveiled.

Colorectal Adenomas

Colorectal adenomas, also known as polyps, are benign growths that develop on the lining of the colon or rectum.
Although non-cancerous, they are considered precursors to colorectal cancer, often developing slowly over time.
The APPROVe trial was particularly important as it focused on patients with a history of such adenomas to determine if Vioxx could prevent their recurrence.
This study targeted individuals with a high risk of further polyp development, aiming to extend the benefits of Vioxx beyond its existing arthritis indications.
The identification and regular monitoring of colorectal adenomas through routine screening, such as colonoscopies, are crucial steps in preventing progression to cancer.

Cardiovascular Events

Cardiovascular events include incidents like heart attacks and strokes, which can result from various risk factors, including medication side effects.
In the context of the APPROVe trial, a notable discovery was the incidence of such events among participants taking Vioxx.
Out of the total number of cardiovascular events recorded during the trial, 46 of them occurred within the group receiving Vioxx, compared to 26 in the placebo group.
This significant difference raised concerns about the safety profile of Vioxx, ultimately leading to the cessation of the clinical trial.
Preventing cardiovascular events is a key focus in many clinical trials, as these outcomes can severely impact patient health and alter the course of treatment development.

Placebo

A placebo is an inactive substance or treatment that mimics the form of the actual drug being tested in a clinical trial.
Its primary purpose is to serve as a control to help determine the true efficacy and safety of the drug under evaluation.
In the APPROVe trial, the placebo group was composed of participants who received an inert substance instead of Vioxx.
Neither the participants nor the healthcare providers knew which individuals were receiving Vioxx or the placebo, a method known as "blinding" designed to eliminate bias.
This helps ensure that observed effects in the trial are due to the drug itself rather than other factors, reinforcing the robustness and reliability of the trial results.